ArticleAmerican journal of translational research2024
Safety and effectiveness of dual trigger (GnRH agonist + HCG) versus HCG alone in patients with high ovarian response.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Empty Follicle Syndrome: Current Therapeutic Approaches and the Role of Triggering Agents in Assisted Reproductive Technology.Medical sciences (Basel, Switzerland) · 2026Review
- The Effect of Retinoic Acid and Bevacizumab on Ovarian Hyperstimulation Syndrome.Journal of clinical practice and research · 2025Article
- Impact of Elevated Oestrogen Levels on hCG Trigger Day on Clinical Pregnancy Outcome and OHSS Incidence in Long-Acting GnRHa Down-Regulated IVF/ICSI-ET Cycles.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the safety and effectiveness between long-term GnRH agonist plus HCG (dual trigger) and HCG trigger alone in high ovarian responders.
methodsA retrospective study was conducted on clinical data from 314 cases of high ovarian response who underwent in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment at Hunan Provincial Maternal and Child Healthcare Hospital from July 2018 to January 2023. Participants were divided into two groups based on their triggering regimen: the Combined treatment group (GnRH agonist + HCG) and the HCG group (HCG alone). Blood routine, ovary ultrasound parameters, baseline hormone levels, clinical outcomes of controlled ovarian stimulation, clinical outcomes of the first transplantation, and incidence of ovarian hyperstimulation syndrome (OHSS) were compared between the two groups.
resultsThere were no significant differences in patient characteristics, blood routines, ovary ultrasound parameters, clinical pregnancy rate, implantation rate and abortion rate between the two groups (all P > 0.05). However, the incidence of Ovarian Hyperstimulation Syndrome (OHSS) in combined treatment group was significantly lower than that in HCG group (mild OHSS: 31% vs. 46.26%, P=0.015; moderate/severe OHSS: 3.00% vs. 11.68%, P=0.021).
conclusionLong-term GnRH agonist plus HCG (dual trigger) does not affect the number of metaphase II (MII) oocytes, high-quality embryos, or clinical pregnancy rate in patients with high ovarian response. Furthermore, the incidence of OHSS is significantly lower with the dual trigger compared to the HCG trigger alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.